Autoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma

Basit Öğe Kaydı
dc.contributor.authorDogan, Bercem Aycicek
dc.contributor.authorArduc, Ayse
dc.contributor.authorTuna, Mazhar Muslum
dc.contributor.authorBerker, Dilek
dc.contributor.authorDemirci, Nilgun
dc.contributor.authorDemirtas, Semra
dc.contributor.authorCicekcioglu, Hulya
dc.date.accessioned2024-04-24T17:18:35Z
dc.date.available2024-04-24T17:18:35Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractAim: Cabergoline is related to an elevated risk of fibrotic adverse reactions including cardiac valvular and pleuropulmonary fibrosis. We investigated pulmonary and cardiac valve fibrosis and immunological markers before and after 3 and 12 months of treatment with cabergoline in women with prolactinoma. Material-Methods: The study included thirty-two women with newly diagnosed prolactinoma and 28 healthy women. CAB cumulative dose was 7.8 +/- 5.5 mg after 3-month therapy, and 31 +/- 22 mg after 12-month follow-up. The risk of autoimmune adverse fibrotic reactions related to CAB treatment including cardiac valvulopathy and pulmonary fibrosis were assessed by a transthoracic echocardiography and pulmonary function tests, respectively. Immunological markers including Antistreptolysin O, Rheumatoid factor, Immunglobuline E, Antinuchlear antibody were also evaluated. Results: Before the start of CAB therapy, the total prevalence of trace grade of mitral, aortic, pulmonic, and tricuspid valve regurgitations were found as 34%, 3%, 6.3%, and 39 % respectively in women with prolactinoma. After improving of prolactin levels with CAB treatment, no change was found in the prevalence of the all valve regurgitations. There was no deterioration in pulmonary function tests. Rheumatoid factor was found higher in newly diagnosed women with prolactinoma than in healthy women (p=0.01), and this was improved by CAB therapy (p=0.005). Conclusion: The prospective study indicated that sufficient cabergoline doses for a period of one year treatment of prolactinoma were not found to be related to fibrotic adverse reactions including cardiac valvular and pulmonary fibrosis or increased levels of immunological marker, apart from rheumatoid factor. For the first time Rf was found higher in newly diagnosed women with prolactinoma and was improved after cabergoline therapy.en_US
dc.identifier.doi10.2174/1871530316666160229120142
dc.identifier.endpage55en_US
dc.identifier.issn1871-5303
dc.identifier.issn2212-3873
dc.identifier.issue1en_US
dc.identifier.pmid26924497
dc.identifier.scopus2-s2.0-84973594580
dc.identifier.scopusqualityQ2
dc.identifier.startpage47en_US
dc.identifier.urihttps://doi.org/10.2174/1871530316666160229120142
dc.identifier.urihttps://hdl.handle.net/11468/18838
dc.identifier.volume16en_US
dc.identifier.wosWOS:000377709800009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofEndocrine Metabolic & Immune Disorders-Drug Targets
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAutoimmune Adverse Fibrotic Reactionsen_US
dc.subjectCabergoline Treatmenten_US
dc.subjectProlactinomaen_US
dc.titleAutoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinomaen_US
dc.titleAutoimmune Fibrotic Adverse Reactions in One-Year Treatment with Cabergoline for Women with Prolactinoma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu